Recent Press Releases

October 2018

Castle Creek Pharma Announces $71.8 Million in New Investment to Expand Research for Rare Dermatologic Conditions

Castle Creek Pharma secures new investment from Fidelity Management & Research Company and Valor Equity Partners towards the late stage [...]

August 2018

Castle Creek Pharmaceuticals Receives FDA Fast Track Designation for Diacerein 1% Ointment for Treatment of Epidermolysis Bullosa Simplex

Biopharmaceutical company currently evaluating diacerein 1% ointment (CCP-020) in ongoing DELIVERS study PARSIPPANY, NJ – August 9, 2018 – Castle [...]

June 2018

Castle Creek Pharmaceuticals Announces First Patient with Epidermolysis Bullosa Enrolled in Pharmacokinetics Study of Diacerein 1% Ointment

New multi-center Phase 1 study expected to enroll up to 20 people living with rare genetic condition that leads to [...]

May 2018

Castle Creek Pharmaceuticals Receives FDA Rare Pediatric Disease Designation for Diacerein 1% Ointment for Epidermolysis Bullosa

Castle Creek Pharmaceuticals Receives FDA Rare Pediatric Disease Designation for Diacerein 1% Ointment for Epidermolysis Bullosa PARSIPPANY, N.J., May 16, [...]

January 2018

Castle Creek Pharmaceuticals to Participate in 5th Annual Dermatology Summit

Biopharma company developing therapies for orphan dermatologic conditions to present during Entrepreneurial Company Showcase. PARSIPPANY, NJ – January 3, 2018 [...]

October 2017

Castle Creek Pharmaceuticals Announces Hiring of Dr. Amir Tavakkol as Executive Vice President and Chief Development Officer

PARSIPPANY, NJ – October 30, 2017 – Castle Creek Pharmaceuticals (CCP), a global company dedicated to delivering transformative therapies to [...]

Castle Creek Pharmaceuticals Receives Partners in Progress Award from debra of America

Company recognized for clinical research in epidermolysis bullosa simplex at the 19th Annual debra of America Benefit PARSIPPANY, NJ – [...]

September 2017

Castle Creek Pharmaceuticals Announces First IGA Scale for Epidermolysis Bullosa Simplex Clinical Research

Company also presents findings from proof-of-concept study of diacerein 1% ointment at 47th Annual ESDR Meeting 2017. PARSIPPANY, NJ – [...]

June 2017

Castle Creek Pharmaceuticals Announces First Patient Enrolled in DELIVERS Study of Diacerein 1% Ointment for Epidermolysis Bullosa Simplex

International randomized, double-blind, parallel group Phase 2/3 clinical trial to evaluate safety and efficacy of potentially disease-modifying therapy PARSIPPANY, NJ [...]

March 2017

© 2016 Castle Creek Pharma  -  Terms & Conditions  -  Privacy Policy

Powered by AmericanEagle.com